FDA GLP-1 Green List: What Changed in the October 2026 Import Alert

The FDA <a href="https://glp1place.com/tools/compound/glp-1/”>GLP-1 Green List is becoming a more detailed quality-control system for imported active pharmaceutical ingredients, not a shortcut around drug approval. On October 9, 2026, the U.S. Food and Drug Administration revised Import Alert 66-80, titled “Detention Without Physical Examination of Glucagon-Like Peptide-1 Receptor Agonist Bulk Drug Substances.” The revision adds new orforglipron entries, creates additional product codes, and explains the records manufacturers should submit if they want FDA to remove their products from routine detention.

The update matters because it shifts attention beyond whether a vial is labeled “<a href="https://glp1place.com/tools/compound/semaglutide/”>semaglutide” or “tirzepatide.” FDA is examining the manufacturing system behind imported active pharmaceutical ingredients, or APIs. An API is the drug substance that produces the pharmacologic effect in a finished medicine. If an API is contaminated, incorrectly characterized, too weak, too strong, or made under poor controls, later compounding or manufacturing may not correct the problem.

FDA’s current alert says it evaluated 48 GLP-1 API sites through inspections and remote records requests. Twenty-one percent were noncompliant under section 501 of the Federal Food, Drug, and Cosmetic Act. The agency also described a pattern in which some firms registered as manufacturers, offered products for import, failed to answer FDA records requests, and then deregistered. FDA’s October 9 Import Alert 66-80 is therefore both an import-enforcement document and a snapshot of the agency’s concerns about the international GLP-1 supply chain.

This is not a new FDA approval pathway for unapproved GLP-1 medicines. It does not authorize consumers to buy imported APIs. It does not certify every compound sold with a research label. It also does not mean every foreign-made API is defective. Instead, the alert describes how FDA field offices may detain covered shipments unless a listed manufacturer and product meet the agency’s criteria for exclusion from detention without physical examination.

What changed in the FDA GLP-1 Green List update?

The October 9 revision makes four important changes. First, FDA added orforglipron API entries for three manufacturers to the Green List. Second, it added an orforglipron drug-product intermediate, described as orforglipron SDD, for one manufacturer. Third, it added a new FDA product code for orforglipron. Fourth, it added product codes for certain hormone products that may otherwise be difficult to classify during import review.

These changes are technical, but product codes affect how shipments are screened. Import codes help FDA field personnel identify the substance, its intended manufacturing use, and the type of article entering the country. The alert now includes a code beginning with 61P for orforglipron and several 64R codes for “Hormone N.E.C.,” meaning hormone products not otherwise classified. The latter codes cover nonsterile powder, sterile powder, active pharmaceutical ingredients for further manufacturing, and ingredients described for prescription compounding.

The Green List includes entries involving several established and investigational metabolic compounds. Depending on the manufacturer and product code, the alert identifies semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and orforglipron. The broader import-alert charge also lists categories that include lixisenatide, insulin degludec, and insulin glargine. Their appearance in the document does not mean all of these substances receive the same treatment at every port. The listed manufacturer, product description, country, and code matter.

The practical point is simple: Green List status is product- and manufacturer-specific. It is not a blanket status for a country, a compound, or every shipment that uses a familiar name.

Why FDA is focusing on imported GLP-1 APIs

The alert links the current enforcement approach to the rapid expansion of GLP-1 compounding during shortages of approved products. During that period, compounders and other organizations sought API supplies from manufacturers in China, India, Europe, and elsewhere. FDA states that GLP-1 APIs are drugs under federal law because they are intended to become components of finished drug products. As a result, they must be manufactured in accordance with current good manufacturing practice, commonly called CGMP.

CGMP is a system of controls designed to ensure that drugs are consistently made and tested to the required standard. It covers more than a final purity number. It includes raw-material controls, validated processes, equipment qualification, laboratory methods, batch records, stability testing, deviation investigations, complaint handling, and the quality unit’s independence and authority.

This distinction is especially important for peptide products. A certificate of analysis may report high assay or purity, but one document cannot establish that a manufacturing site has controlled every relevant risk. FDA’s alert specifically requests information about impurity specifications, potency, microbial attributes for APIs intended for injectable products, stability protocols, starting materials, laboratory validation, process validation, batch records, equipment, out-of-specification results, standard operating procedures, and adverse-event or recall history.

GLP1Place has previously explained why impurity profiles and batch identity deserve more attention than a large percentage printed on a certificate. The 2026 compounded GLP-1 impurity study is relevant context, although it is separate from this FDA import action. The study does not prove that every imported API is unsafe. It does show why chemical identity and impurity characterization are central scientific questions when products are made outside the originator-drug supply chain.

What “detention without physical examination” means

Detention without physical examination, or DWPE, is an FDA import-control mechanism. Under an import alert, FDA field personnel may detain an article without physically examining or laboratory-testing every shipment. The agency uses available information to identify products that appear adulterated, misbranded, or otherwise violative.

DWPE is not the same as a criminal seizure, and it is not a finding that every individual container is defective. It means the shipment may be held unless the importer or manufacturer provides sufficient evidence that the article is admissible. The alert gives FDA a way to manage risk at the border when the agency has reason to believe that covered products may violate federal requirements.

For Import Alert 66-80, the principal concern is apparent adulteration connected to CGMP failures. FDA cites section 501(a)(2)(B), which addresses manufacturing methods, facilities, and controls that do not conform to CGMP. The alert also discusses section 501(j), which addresses firms that delay, deny, or limit an inspection or fail to provide requested records.

FDA’s wording matters. The agency does not say that imported GLP-1 APIs are automatically unlawful because they come from outside the United States. It says that foreign-sourced GLP-1 APIs should be considered for detention when available information creates the appearance of adulteration. A manufacturer may seek removal from DWPE by showing that it has corrected the conditions that created that appearance.

What companies must show to leave the detention list

The October revision adds detail to the evidence FDA may expect from a firm seeking Green List placement. The request should identify all physical manufacturing sites and demonstrate that the GLP-1 APIs were manufactured and distributed in compliance with CGMP. FDA’s examples are broad because the agency is evaluating the entire quality system rather than a single laboratory result.

The requested evidence may include:

• Certificates of analysis for the last ten GLP-1 API lots, or every lot if fewer than ten have been made.
• Container labels and distribution information.
• Customer, shipper, consignee, importer, and facility identification details.
• Release specifications and test methods, with scientific justification for impurity, potency, and microbial limits.
• Stability protocols, acceptance criteria, testing intervals, and summary results.
• Specifications and testing reports for starting materials.
• Validation or verification reports for release testing.
• Process-validation protocols and reports.
• Master batch records and recent manufacturing batch records.
• Equipment lists, including qualification dates and whether equipment is shared or dedicated.
• Out-of-specification results, investigations, and final lot-disposition decisions.
• Standard operating procedures and the organization chart for the quality unit.
• Five years of complaint, adverse-event, recall, and product-return summaries, along with investigation reports.

This list shows the difference between a marketing claim and a regulatory quality assessment. A company may say that a peptide is “99 percent pure,” but FDA may ask how the assay was validated, how impurities were defined, what happened when a batch failed, how the process was qualified, and whether the same controls were used for products distributed in the United States and other markets.

FDA also recommends that submissions be provided in English, with translations and original documents included when necessary. The agency warns that documents not submitted in English may delay review. That detail shows that documentation quality is itself part of the import process.

What the alert means for semaglutide and tirzepatide supply chains

Semaglutide and tirzepatide remain central to the alert because they have been widely used in approved medicines and compounded preparations. FDA says shortages of approved GLP-1 products increased demand for imported APIs used in compounding. The agency also warns that compounders operating under section 503A may not be subject to the same CGMP requirements that apply to API manufacturers.

That does not mean every 503A preparation is automatically defective. It means quality controls at the API stage become especially important because downstream compounding may not provide the same level of impurity and potency control as a fully regulated commercial manufacturing system. If an API has an unknown impurity, an incorrect concentration, or an incomplete stability profile, later preparation of the finished product may not reveal the problem.

FDA’s separate public information on unapproved GLP-1 products reports hundreds of adverse-event reports associated with compounded semaglutide and compounded tirzepatide as of May 31, 2026. The agency cautions that such reports do not always prove causation and may be underreported. Still, the concern helps explain why FDA is examining API suppliers, not only finished products. FDA’s public warning on unapproved GLP-1 drugs also states that unapproved products do not undergo FDA review for safety, effectiveness, and quality before marketing.

For readers, the key distinction is between an approved medicine, a lawfully compounded preparation, an imported bulk substance, and an unapproved product marketed directly to the public. These categories are not interchangeable. A Green List entry for a manufacturer’s API does not convert a separate finished product into an approved medicine.

Why orforglipron is a notable new compound in the update

Orforglipron is notable in the October revision because it is a small-molecule oral GLP-1 receptor agonist rather than a peptide. That chemistry gives it a different manufacturing and formulation profile from semaglutide, tirzepatide, liraglutide, exenatide, and dulaglutide.

The new alert entries do not establish clinical effectiveness, safety, or approval. They show that FDA is adapting its import-classification and manufacturing-review framework as new metabolic compounds move through development and commercial planning. The agency added a product code for orforglipron API and a separate entry for orforglipron SDD, a drug-product intermediate.

This is an example of how regulatory infrastructure can develop alongside a drug pipeline. A compound can have a distinct chemical identity, supply chain, manufacturing process, and customs classification before it becomes an approved finished product. Accurate classification helps FDA identify what is entering the country and determine which compliance framework applies.

It also shows why “peptide” is not a complete description of the metabolic-drug market. Some newer GLP-1 medicines are nonpeptide small molecules. Others are dual or triple receptor agonists. Manufacturing risks, analytical methods, and product codes may differ even when the pharmacologic target is related.

What the October update does not change

The October 9 revision should not be read as a blanket ban on imported GLP-1 APIs. The alert contains a Green List of specified firms and products that have met FDA’s criteria for exclusion from routine DWPE. It also provides a process for firms to submit evidence for removal from detention.

At the same time, Green List status is not a certificate of approval for every product associated with a company. It applies within the scope of the listed product, manufacturer, and import classification. A different facility, API, intermediate, or product code may receive different treatment.

The update also does not legalize the direct sale of unapproved GLP-1 products to consumers. FDA’s warning-letter program has repeatedly stated that labels such as “research use only” do not control the legal analysis when a website’s claims, product combinations, dosing information, or intended-use statements show that a product is being offered as a drug. GLP1Place’s review of the FDA’s GLP-1 generic-drug workshop provides additional context on how the agency is approaching peptide sameness, impurities, immunogenicity, and equivalence.

Finally, the alert does not tell individuals how to select, purchase, reconstitute, or use an API. Bulk drug substances are materials for pharmaceutical manufacturing, not consumer medicines. Their presence in a shipping or customs document should never be treated as evidence that a product is suitable for human use.

How this affects regulatory compliance and industry oversight

The October revision suggests that FDA’s approach is becoming more data-intensive. Earlier public debate often focused on whether a supplier could provide a certificate of analysis. The updated evidence checklist points to a deeper review of manufacturing history, laboratory validation, stability, complaints, deviations, and quality-unit oversight.

That shift may raise the compliance burden for foreign API manufacturers, importers, compounders, and other organizations involved in the GLP-1 supply chain. It may also reduce the usefulness of superficial documentation. A certificate with a high purity percentage is easier to produce than a complete, internally consistent quality record covering ten lots, method validation, process controls, stability, and failed-batch investigations.

For regulators, a detailed checklist improves consistency. For legitimate manufacturers, it gives clearer expectations about the information needed to demonstrate control. For importers, it increases the importance of verifying the actual manufacturing site and the identity of the material entering the country. For consumers, it reinforces a broader lesson: a familiar compound name does not guarantee a familiar quality standard.

The alert also reflects a supply-chain problem rather than a single-product problem. Semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and other metabolic compounds may pass through multiple organizations before becoming a finished drug. Each handoff creates an opportunity for relabeling, incomplete records, incorrect storage, or confusion between an API, an intermediate, and a finished dosage form.

Researcher takeaways from the FDA GLP-1 Green List

Researchers evaluating this development should keep five conclusions in view.

1. Import status is not clinical status. A Green List entry concerns border enforcement and manufacturing evidence. It does not prove clinical benefit or establish that a finished drug is approved.
2. Purity is only one quality attribute. Identity, potency, impurities, microbial quality, stability, process control, and documentation all matter.
3. Manufacturer-specific review is central. The same compound name may appear under different facilities, product codes, and regulatory histories.
4. Orforglipron shows the framework is expanding. FDA is adding classifications for newer small-molecule metabolic agents, not only established peptide APIs.
5. Grey-market labels do not replace regulatory evidence. “Research” language cannot resolve questions about intended use, manufacturing quality, or suitability for human administration.

The central message is not that all imported GLP-1 APIs are unsafe. It is that quality must be demonstrated through a traceable manufacturing system. FDA’s October 9, 2026 revision makes that expectation more explicit and gives the public a clearer view of the records the agency considers meaningful.

Frequently asked questions

What is the FDA GLP-1 Green List?

The FDA GLP-1 Green List is the portion of Import Alert 66-80 that identifies specified manufacturers and products that FDA field offices should generally exclude from routine detention without physical examination. The status is limited to the listed manufacturer, material, and product classification.

What changed on October 9, 2026?

FDA added orforglipron API entries for three manufacturers, added an orforglipron SDD entry for one manufacturer, created a new orforglipron product code, added hormone-related product codes, and expanded the examples of records firms should submit when seeking removal from detention.

Does a Green List entry mean a product is safe for personal use?

No. The Green List is not a consumer safety certification. It concerns import enforcement for bulk substances and specific manufacturing sources. It does not approve a finished medicine or establish that an unapproved product is suitable for human use.

Why does FDA care about API manufacturing?

The API is the active drug substance used to make the finished product. Problems with identity, potency, impurities, microbial quality, stability, or manufacturing controls can affect the final medicine. FDA therefore evaluates the API supply chain as part of its broader quality oversight.

Are semaglutide and tirzepatide banned under this alert?

No. Import Alert 66-80 does not create a blanket ban on semaglutide or tirzepatide APIs. It allows FDA field offices to detain covered shipments that appear adulterated unless the product and manufacturer qualify for an exception or the importer provides sufficient evidence for release.

What should readers understand about online “research” products?

A research label does not establish FDA approval, human-use safety, manufacturing quality, or lawful marketing. The FDA evaluates intended use based on the totality of labeling, claims, product combinations, and surrounding conduct. Bulk APIs and research-labeled compounds should not be treated as consumer medicines.

Bottom line: The October 9, 2026 FDA revision makes the GLP-1 Green List more specific and the evidence required for compliance more demanding. It adds orforglipron classifications, expands import codes, and emphasizes complete manufacturing records. The development is best understood as a quality and supply-chain enforcement update—not as approval, endorsement, or a purchasing pathway for unapproved GLP-1 products.